Search:

Home Index Back issues Contact

 

Volume 7, Number 4

 

Lee Hurst: living with ankylosing spondylitis

Brian Hazleman MA MB FRCP Honorary Consultant in Rheumatology, Addenbrooke’s Hospital, Cambridge

The comedian and TV personality Lee Hurst has lived with ankylosing spondylitis (AS) for over 20 years. Here, he talks to Brian Hazleman about how it has affected his life and work – currently focused on Lee Hurst’s Comedy Club in east London – his coping mechanisms, and his opinions on the treatment available, while Dr Hazleman provides a clinical perspective.

 

Methods of testing for RA

Devesh Mewar BChir MB MRCP Consultant in Rheumatology, Royal Liverpool University Hospital, Liverpool; Gerry Wilson MB PhD FRCP DCH Professor of Rheumatology, University of Sheffield, Royal Hallamshire Hospital, Sheffield

The past ten years have seen major advances in the management of individuals with rheumatoid arthritis (RA). High-quality controlled trials have established the efficacy of conventional disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, as well as an increasing range of newer biologic agents.

 

NICE osteoarthritis guidance

Claire Wenham BMBS MRCP Clinical Research Fellow, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds; Philip Conaghan MB BS PhD FRACP FRCP Professor of Musculoskeletal Medicine, NIHR Leeds Musculoskeletal Biomedical Research Unit and Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds

In February 2008, the National Institute for Health and Clinical Excellence (NICE) issued a comprehensive guide to the care and management of osteoarthritis (OA) in adults. In this article, the authors will draw out the key points from these recommendations with a view to updating front-line clinicians and highlighting areas of potential change in practice.

 

The role of bisphosphonates

Jason Seewoodhary BSc(Hons) MBBCh(Hons) MRCP(UK) Specialist Registrar in Rheumatology and General Medicine; Sarah M Keidel BM BCh(Oxon) MA(Oxon) MRCP(UK) Specialist Registrar in Rheumatology and General Medicine; Sally E Edmonds MBBS MD FRCP(UK) Consultant Rheumatologist, Department of Rheumatology, Stoke Mandeville Hospital, Aylesbury

Osteoporosis is a disorder characterised by low bone mass and microarchitectural deterioration, with a resulting increase in bone fragility and susceptibility to fracture. It is a very important public health issue, because of the high morbidity and mortality of people with fractures. The incidence of osteoporosis-related fractures is increasing and this constitutes a major public health problem.

 

Treatment options for gout

Thomas Rider MBBS BCS F1 Doctor in General Medicine; Kelsey M Jordan MBChB MRCP(UK) Consultant Rheumatologist, Brighton and Sussex University Hospitals Trust

Gout is one of the oldest recognised diseases, first identified by the Egyptians in 2640 BC. Hippocrates later described the disease as ‘arthritis of the rich’, due to its association with rich foods and excessive alcohol. Currently, gout has a prevalence of 1.4% in the UK; this does not appear to be rising, unlike in many other countries around the world.

 

Trusted drugs and new discoveries

Paul Emery, Editor

Can medicines be too successful? This question can be raised with the case of the therapy for gout. The availability of highly successful and specific treatment with allopurinol relegated interest in gout to a very low level for many years.

 

 


The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Rheumatology in practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk